Enterin
PrivateLast Round
Series A
Jul 17, 2017
Total Funding Raised
$12.7M
Company Overview
Enterin is a biotechnology company that develops novel drugs designed to offer treatments that target the gut-brain axis and modify the course of neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enterin Comps
Public and private peers based on sector, stage, and business model.
Enterin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 17, 2017 |
Key People
Founding team and executive leadership
Enterin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Scientia Ventures | Series A, VC Round |
| New Ventures III | Series A |
| The Naissos Group | Series A, VC Round |
| Indie Asset Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2024
Monthly visitors grew 1000% MoM, from 70 to 770.
- Jul 17, 2017
$13M round led by New Ventures III.
Enterin Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Enterin's valuation, stock price, and market status.
